Healthline
November 14, 2025
Share on PinterestThe TrumpRx prescription drug savings program is expected to be available by early 2026. Eli Lilly and Novo Nordisk have agreed to sell their […]
November 12, 2025
Share on PinterestThe FDA will remove black box warning labels on HRT products, which the agency states has sown confusion around hormone therapy for menopause. Lupe […]
November 12, 2025
Share on PinterestAcetaminophen is the safest option for pain relief and lowering fever during pregnancy. Anfisa&friends/Stocksy A new research review disputes claims made by the Trump […]
November 11, 2025
Share on PinterestA new clinical trial found that coffee drinkers with AFib had a significantly lower risk of recurrence. Boy_Anupong/Getty Images A new clinical trial challenges […]
Medscape
July 8, 2025
Obesity often brings about, or exacerbates, depression and anxiety. Yet some of the most effective drugs for managing depression are also known to cause weight gain. […]
July 8, 2025
Despite dramatic treatment advances in recent years, the dermatology community has lacked a unified definition for what remission means in plaque psoriasis. Now, a multistage Delphi […]
July 8, 2025
Could a simple advisory or alert in the electronic medical record (EMR) be the key to more frequent diagnosis and effective treatment of high blood pressure […]
July 8, 2025
In young children, the long-term effects of SARS-CoV-2 infection may differ significantly from those in older children or adults. A recent study in JAMA Pediatrics systematically […]
FDA
November 13, 2025
Action FDA approved Poherdy (pertuzumab-dpzb) injection as an interchangeable biosimilar biological product to Perjeta (pertuzumab). Poherdy (pertuzumab-dpzb) is the first biosimilar approved for Perjeta (pertuzumab). Poherdy […]
November 13, 2025
AAM GRx+Biosims, North Bethesda, MD October 28, 2025 FDA Electronic Submissions (EXPO BOOTH) – Jonathan Resnick, Heather Crandall, Seyoum Senay, Megan Boals, Sajid Khan, Office of […]
November 13, 2025
On November 13, 2025, the Food and Drug Administration approved Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics Co. Ltd.) as an interchangeable biosimilar to Perjeta (pertuzumab, Genentech Inc.). […]
November 13, 2025
On November 13, 2025, the Food and Drug Administration approved ziftomenib (Komzifti, Kura Oncology, Inc.), a menin inhibitor, for adults with relapsed or refractory acute myeloid […]
